Arca
Skip to content
Tools
Tools

PDE3A: cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A

Cyclic nucleotide phosphodiesterase with specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.

  • Drugs that act on it: 5
  • Approved: 5
  • In phases 1 to 3: 0
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on PDE3A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 5

Approved5

  • Cilostazol
  • Milrinone
  • Inamrinone
  • Ibudilast
  • Dyphylline

Phase 30

    Phase 20

      Phase 10

        Sponsors

        Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Phosphodiesterase 3A inhibitor.
        CilostazolBoxed warningApprovedOtsuka PharmaceuticalSmall moleculeInhibitor28
        MilrinoneApprovedSanofiSmall moleculeInhibitor14
        InamrinoneApprovedSanofiSmall moleculeInhibitor8
        IbudilastApprovedMediciNovaSmall moleculeInhibitor2
        DyphyllineApprovedTeva Pharmaceutical IndustriesSmall moleculeInhibitor1

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 23 in all, from ClinicalTrials.gov.
        Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial Stenosis: A Real-World Cohort StudyCilostazol—RecruitingSecond Affiliated Hospital of Soochow UniversityNov 13, 2026
        Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial StenosisCilostazolPhase 4RecruitingSecond Affiliated Hospital of Soochow UniversityNov 12, 2026
        Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation TherapyCilostazolPhase 3Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineAug 5, 2026
        Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 DiabetesCilostazolPhase 4RecruitingSeoul National University Bundang HospitalJul 22, 2026
        Endovascular Therapy for Cerebral Vasospasm After Aneurysmal Subarachnoid HemorrhageMilrinoneNot applicableNot yet recruitingBeijing Tiantan HospitalJun 12, 2026
        Efficacy and Safety of Indobufen, Aspirin, Cilostazol and Clopidogrel in the Treatment of Ischemic StrokeCilostazol—Not yet recruitingNanfang Hospital, Southern Medical UniversityMay 22, 2026
        Relying on Pharmacotherapy to Improve Motor Gains in Chronic Stroke SurvivorsCilostazolEarly phase 1RecruitingSpaulding Rehabilitation HospitalMay 15, 2026
        Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion(REPAIR)CilostazolNot applicableNot yet recruitingFeng GaoMar 27, 2026
        Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES TrialCilostazolPhase 1Not yet recruitingFudan UniversityDec 16, 2025
        Outcome of Clinical Phenotypes of Pediatric Myocarditis at Assiut University Children HospitalMilrinone—Not yet recruitingAssiut UniversitySep 16, 2025
        Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid HemorrhageMilrinonePhase 3Not yet recruitingCentre Hospitalier St AnneAug 28, 2025
        Comparison of Milrinone and Epinephrine on TAPSEInamrinone, MilrinoneNot applicableRecruitingMansoura UniversityAug 27, 2025
        Milrinone for Prevention of Post-ligation Cardiac Syndrome TrialMilrinonePhase 3RecruitingNICHD Neonatal Research NetworkNov 8, 2024
        Cardiac Power Output in Cardiogenic Shock PatientsInamrinone, MilrinoneEarly phase 1RecruitingUniversity of ChicagoJan 26, 2023
        Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass SeparationInamrinone, MilrinonePhase 2RecruitingMontreal Heart InstituteJul 8, 2022
        Ibudilast for Treating Alcohol Use DisorderIbudilastPhase 2Active, not recruitingUniversity of PennsylvaniaJun 10, 2022
        CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic ShockInamrinone, MilrinonePhase 4RecruitingOttawa Heart Institute Research CorporationMar 4, 2022
        Opportunistic PK/PD Trial in Critically Ill Children (OPTIC)Inamrinone—RecruitingDuke UniversitySep 24, 2021
        Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary HypertensionInamrinonePhase 4RecruitingZagazig UniversityJul 23, 2020
        Cerebral Hemodynamic Optimization by Milrinone to Prevent Delayed Cerebral IschemiaInamrinonePhase 2Active, not recruitingUniversity Hospital, ToulouseFeb 25, 2020
        Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Inamrinone—RecruitingDuke UniversityFeb 20, 2020
        Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALSIbudilastPhase 2 / Phase 3Active, not recruitingMediciNovaAug 15, 2019
        DILIN - Prospective StudyDyphylline—RecruitingDuke UniversityJun 29, 2006

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        Brachydactyly-arterial hypertension syndrome
        0.78
        Coronary artery disorder
        0.68
        Cardiovascular disorder
        0.67
        Stroke disorder
        0.66
        Hypertensive disorder
        0.63
        Asthma
        0.60
        Airway obstruction
        0.57
        Congestive heart failure
        0.54

        Genes and related targets

        Complexes and families that share a gene with this target
        Genes
        PDE3A

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL241, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q14432, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.